C&G Editor in Chief, Erin Harris

  1. Mammoth Biosciences On Epigenetic Editing 8/29/2024

    In case you missed it, this is a summary of Cell & Gene: The Podcast Episode 81 featuring Mammoth Biosciences' Lucas Harrington.

  2. Gamma-Delta T-Cell Therapy for AML 8/29/2024

    William Ho, CEO at IN8bio, shares the company’s progress with gamma-delta T-cell-based immunotherapies and why they represent a groundbreaking approach in oncology, including treatment for Acute Myeloid Leukemia (AML).

  3. The Role Of Stem Cell Biology, Machine Learning, And Laser Optics On Regenerative Medicine 8/16/2024

    Cellino Biotech's CEO, Nabiha Saklayen, Ph.D., explains how the company plans to make personalized regenerative medicines viable at large scale for the first time.

  4. Umoja Biopharma's Potential for First In Vivo CAR T To Enter Clinic 7/31/2024

    Umoja Biopharma's Dr. Andy Scharenberg and David Fontana discuss the company's expectations for UB-VV111 to potentially become the first in vivo CAR T cell therapy to enter the clinic in the U.S. 

  5. Breaking Down The FDA Draft Guidance, "Rare Diseases: Considerations For The Development Of Drugs And Biological Products" 7/24/2024

    Raj Bandaru, Associate Director in Regulatory Affairs and U.S. Regulatory Affairs Lead at Accenture provides rich context on parts of the recent FDA Draft Guidance.

  6. Regulatory T Cells & Autoimmune Disease 7/9/2024

    KSQ's Micah Benson shares information about the company's approach to treating autoimmune disease.

  7. What Are Smart mRNAs? 7/1/2024

    Strand Therapeutics' programmable, "smart," mRNA therapeutics could deliver precise, potentially curative treatments for solid tumors and hematological malignancies.

  8. mRNA Delivering Full-length Dystrophin for DMD 6/24/2024

    Elixirgen Therapeutics' Aki Ko shares that is conceivable that delivery of a normal, full-length dystrophin protein would address issues seen with other dystrophin replacement approaches for DMD.

  9. New Report Solidifies Greater Philadelphia Region as Global CGT Leader 5/30/2024

    A new comprehensive regional snapshot of the CGT industry shows how cell and gene therapy has become one of the most important economic drivers in the Greater Philadelphia Region over the past decade.

  10. Pediatric Patient Access With Dr. Bambi Grilley 5/29/2024

    ISCT's Chief Regulatory Officer, Dr. Bambi Grilley, Ph.D., shares insight on CGT's global regulatory landscape and the differences between the pediatric and adult patient journey.